NEW YORK - Delcath Systems, Inc. (NASDAQ:DCTH), an interventional oncology company specializing in liver cancer treatments, has announced the addition of Dr. Bridget Martell to its Board of Directors, effective May 23, 2024. This strategic appointment comes as Delcath continues to focus on improving patient outcomes through its proprietary liver cancer treatments.
Dr. Martell brings a wealth of experience to Delcath, having held various senior management and director roles in the biotechnology sector. Her expertise in oncology clinical development is expected to be a significant asset to the company.
Currently, she serves as an independent director at Aligos Therapeutics (NASDAQ:ALGS) and Achieve Life Sciences (NASDAQ:ACHV). Her past roles include director positions at POINT Biopharma Global, Inc. and Ayala Pharmaceuticals, highlighting her extensive background in the field.
John Sylvester, Chairman of the Delcath Board of Directors, expressed confidence in Dr. Martell's ability to contribute to the company's mission. Dr. Martell herself is enthusiastic about joining the board at a pivotal time in Delcath's growth.
Delcath Systems is known for its HEPZATO KIT™ and CHEMOSAT® Hepatic Delivery System for Melphalan, which are used to deliver high-dose chemotherapy to the liver while minimizing systemic exposure and side effects.
The HEPZATO KIT is approved in the United States for treating metastatic uveal melanoma with specific criteria. In Europe, the CHEMOSAT system is approved as a Class III medical device for various liver cancers.
This news is based on a press release statement issued by Delcath Systems, Inc.
InvestingPro Insights
As Delcath Systems, Inc. (NASDAQ:DCTH) welcomes Dr. Bridget Martell to its Board of Directors, the company's financial health and market performance remain crucial for investors monitoring its progress in the competitive biotechnology sector.
According to InvestingPro data, Delcath Systems currently has a market capitalization of $215.06 million, underscoring its position in the market. Notably, the company's revenue growth over the last twelve months as of Q1 2024 stands at an impressive 56.81%, indicating a strong upward trajectory in sales.
InvestingPro Tips for Delcath Systems highlight a few key aspects of the company's current financial standing. First, Delcath holds more cash than debt on its balance sheet, which is a positive sign of financial stability. Moreover, analysts anticipate sales growth in the current year, which could be promising for potential investors looking for growth opportunities. However, the company is not expected to be profitable this year, and the stock's Relative Strength Index (RSI) suggests it is currently in overbought territory.
For those interested in a deeper dive into Delcath Systems' financials and performance metrics, there are over 12 additional InvestingPro Tips available. These can provide further insights into the company's valuation, profitability, and stock performance over various timeframes. To explore these tips and make more informed investment decisions, use the coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro.
Investors may also note that Delcath Systems does not pay a dividend, which could be a consideration for those seeking income-generating investments. However, with the appointment of Dr. Martell and the company's focus on innovative liver cancer treatments, Delcath Systems continues to be a company to watch in the biotech industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.